Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-HT1F agonists

c1 26 26 37 37 2 13 36 13 1 26 26 2 3a3b 3c3c3a3b3c 4 13 5 13 36 3a 5 6 16 1F The present invention relates to compounds of formula I: or a pharmaceutically acceptable acid addition salt thereof, wherein X is C(R3)═ or N═; Ris C-Calkyl, substituted C-Calkyl, C-Ccycloalkyl, substituted C-Ccycloalkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; Ris hydrogen, C-Cn-alkyl, C-Ccycloalkyl-C-Calkyl, or a group of formula II provided that when Ris C-Calkyl or substituted C-Calkyl, Ris hydrogen or methyl; R, Rand, when X is -C(R)═, R, are each independently hydrogen, fluoro, or methyl, provided that no more than one of R, R, and Rmay be other than hydrogen; Ris hydrogen or C-Calkyl; Ris hydrogen, C-Calkyl, or C-Ccycloalkylcarbonyl, provided that when Ris other than hydrogen, Ris hydrogen; Ris hydrogen or C-Calkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5HTreceptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal.